Sign In

Tony Zhang

Biopharmaceutical research and development

Tony Zhang is the CEO and founder of Tyligand Bioscience, a clinical-stage biotechnology company focused on developing innovative cancer therapies.1 He has a Ph.D. in biochemistry from Case Western Reserve University and extensive experience in the pharmaceutical and biotechnology industries.2

Zhang's career highlights include:

  1. Co-founder and CEO of BlueJay Mobile-Health, Inc., developing telehealth and mobile technologies for health providers.2
  2. Co-founder and CEO of Formurex, Inc., a contract research organization providing services in preformulation, formulation, and advanced drug delivery.2
  3. Co-founder and Vice President of Epitomics, Inc., where he was in charge of developing antibody technologies.2
  4. Senior Scientist at Bayer Corporation, responsible for high throughput screening of drug candidates.2
  5. Postdoctoral fellow at Genentech, working on the discovery of new genes.2

Under Zhang's leadership, Tyligand Bioscience has recently announced the dosing of the first patient in a Phase 1/2 clinical trial of TSN1611, a selective and orally bioavailable KRAS G12D inhibitor for the treatment of KRAS G12D mutant solid tumors.1

Highlights

May 24 · biospace.com
Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 ...
Jan 1 · ventureradar.com
Tyligand Bioscience - VentureRadar

Related Questions

What is Tony Zhang's educational background?
What other companies has Tony Zhang founded or led?
What is the significance of the KRAS G12D mutation in cancer treatment?
How does TSN1611 compare to other KRAS inhibitors?
What are the main goals of the Phase 1/2 trial for TSN1611?
Tony Zhang
Tony Zhang, photo 1
Tony Zhang, photo 2
Add to my network

Location

Pudong, Shanghai, China